Skip to content
value.today

Click Therapeutics, Inc.

🇺🇸 New York, New York, USAHealth CareFounded 2012
Total raised
$178 M
8 rounds on record
Latest round
$50 M
Apr 2026
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Click Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$50 MNo. 8$50 to $250 million

Click Therapeutics, Inc.: Raise no. 8, Apr 2026

Investors in this round

1 investor had bought by the notice of Oct 1, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David B. Klein · Executive Officer, Director
  • Randall Stanicky · Executive Officer
  • Alex Zisson · Director
  • Anthony Costello · Director
  • Bruce Robertson · Director · Mr. Robertson was elected a Director after the Date of First Sale and resigned prior to the date hereof.
  • Cris De Luca · Director
  • David Friedman · Director
  • Douglas Langa · Director · Mr. Langa was elected a Director after the Date of First Sale.
  • Jeffrey Berkowitz · Director
  • Lezrene Cunningham · Director · Ms. Cunningham served as a Director on the date that the board approved the Offering and on the Date of First Sale. She
  • Maria Forero · Director
  • Muzammil Mansuri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David B. Klein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 1, 2026. Read the notice at the SEC.

equitySEC
Mar 2025$49 MNo. 7$10 to $50 million

Click Therapeutics, Inc.: Raise no. 7, Mar 2025

Investors in this round

3 investors had bought by the notice of Apr 1, 2025: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$49 M of $49 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David B. Klein · Executive Officer, Director
  • Randall B. Stanicky · Executive Officer
  • Alex B. Zisson · Director
  • Anthony B. Costello · Director · Mr. Costello was elected a director upon the effectiveness of the Offering.
  • Cris B. De Luca · Director
  • David B. Friedman · Director
  • Jeffrey B. Berkowitz · Director
  • Lee B. Shapiro · Director
  • Lezrene B. Cunningham · Director
  • Maria B. Forero · Director
  • Muzammil B. Mansuri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Amount Sold includes converted debt in the aggregate amount of $8,577,028.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David B. Klein, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 1, 2025. Read the notice at the SEC.

equitySEC
May 2024$3 MNo. 6$2 to $10 million

Click Therapeutics, Inc.: Raise no. 6, May 2024

Investors in this round

1 investor had bought by the notice of Nov 21, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Klein · Executive Officer, Director
  • Randall Stanicky · Executive Officer
  • Alex Zisson · Director
  • Cris De Luca · Director
  • Jeffrey Berkowitz · Director
  • Lee Shapiro · Director
  • Lezrene Cunningham · Director
  • Maria Forero · Director
  • Muzammil Mansuri · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David B. Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 21, 2024. Read the notice at the SEC.

equitySEC
Oct 2021$52 MNo. 5$50 to $250 million

Click Therapeutics, Inc.: Raise no. 5, Oct 2021

Investors in this round

9 investors had bought by the notice of Nov 5, 2021: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$52 M of $52 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Klein · Executive Officer, Director
  • Randall Stanicky · Executive Officer
  • Alex Zisson · Director · Mr. Zisson was elected as a director in connection with the offering.
  • Cris De Luca · Director
  • Jeff Berkowitz · Director
  • Lee Shapiro · Director
  • Muzammil Mansuri · Director
  • Uri Geiger · Director · Mr. Geiger was elected as a director in connection with the offering.

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David B. Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 5, 2021. Read the notice at the SEC.

equitySEC
Jun 2018$17 MNo. 4$10 to $50 million

Click Therapeutics, Inc.: Raise no. 4, Jun 2018

Investors in this round

50 investors had bought by the notice of Jun 28, 2018: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $19 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Klein · Executive Officer, Director
  • Ted Silver · Executive Officer
  • John Sadowski · Director
  • Nicholas Schork · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Jun 28, 2018. Read the notice at the SEC.

equitySEC
Apr 2017$4 MNo. 3$2 to $10 million

Click Therapeutics, Inc.: Raise no. 3, Apr 2017

Investors in this round

11 investors had bought by the notice of Apr 20, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in New York

People named in the notice

  • David Klein · Executive Officer, Director
  • Emile Westergaard · Director
  • Nicholas Schork · Director
  • Victor Gao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Apr 20, 2017. Read the notice at the SEC.

debt, optionsSEC
Jul 2015$2 MNo. 2Under $2 million

Click Therapeutics, Inc.: Raise no. 2, Jul 2015

Investors in this round

18 investors had bought by the notice of Aug 6, 2015: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$63,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in New York

People named in the notice

  • David Klein · Executive Officer, Director
  • Emile Westergaard · Director
  • Nicholas Schork · Director
  • Victor Gao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Emerson Equity LLC (CRD 130032) · broker-dealer Jonathan Sadowsky (CRD 2911276) · San Mateo, CaliforniaSold in DC, FL, MA, NY, PA, TN

Remarks in the notice

  • On fees: “The fee paid to the placement agent included a cash payment of $63,500 and warrants to purchase 63,500 shares of the company's Common Stock.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Aug 6, 2015. Read the notice at the SEC.

debt, optionsSEC
Oct 2014$1 MNo. 1Under $2 million

Click Therapeutics, Inc.: Raise no. 1, Oct 2014

Investors in this round

13 investors had bought by the notice of Nov 4, 2014: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$109,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in New York

People named in the notice

  • David Klein · Executive Officer, Director
  • Emile Westergaard · Director
  • Nicholas Schork · Director
  • Victor Gao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Marta Zylka (CRD 5578030) · broker-dealer Merriman Capital, Inc. (CRD 18296) · New York, New YorkSold in WA
  • Zvi Ben-Zvi (CRD 2994766) · broker-dealer Merriman Capital, Inc. (CRD 18296) · New York, New YorkSold in FL, MN, NJ, NY, TN, TX

Remarks in the notice

  • On fees: “The fee paid to the placement agent included a cash payment of $109,000.00 and a warrant to purchase 167,692 shares of the company's Common Stock.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by David Klein, President and CEO. Source: SEC Form D, newest notice filed Nov 4, 2014. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Click Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Oct 2026

That is all the official record says: Click Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Click Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Click Therapeutics, Inc.
NameRoleNamed in
David B. KleinExecutive officerApr 2025
Randall B. StanickyExecutive officerApr 2025
David KleinExecutive officerNov 2024
Randall StanickyExecutive officerNov 2024
Ted SilverExecutive officerJun 2018
Anthony CostelloDirectorOct 2026
Bruce RobertsonMr. Robertson was elected a Director after the Date of First Sale and resigned prior to the date hereof.Oct 2026
David FriedmanDirectorOct 2026
Douglas LangaMr. Langa was elected a Director after the Date of First Sale.Oct 2026
Alex B. ZissonDirectorApr 2025
Anthony B. CostelloMr. Costello was elected a director upon the effectiveness of the Offering.Apr 2025
Cris B. De LucaDirectorApr 2025
David B. FriedmanDirectorApr 2025
David B. KleinDirectorApr 2025
Jeffrey B. BerkowitzDirectorApr 2025
Lee B. ShapiroDirectorApr 2025
Lezrene B. CunninghamDirectorApr 2025
Maria B. ForeroDirectorApr 2025
Muzammil B. MansuriDirectorApr 2025
Alex ZissonDirectorNov 2024
Cris De LucaDirectorNov 2024
David KleinDirectorNov 2024
Jeffrey BerkowitzDirectorNov 2024
Lee ShapiroDirectorNov 2024
Lezrene CunninghamDirectorNov 2024
Maria ForeroDirectorNov 2024
Muzammil MansuriDirectorNov 2024
Jeff BerkowitzDirectorNov 2021
Uri GeigerMr. Geiger was elected as a director in connection with the offering.Nov 2021
John SadowskiDirectorJun 2018
Nicholas SchorkDirectorJun 2018
Emile WestergaardDirectorApr 2017
Victor GaoDirectorApr 2017